tegaserod
Trade name: zelnorm
Approved
Jul 24, 2002
Tegaserod (3‐(5‐methoxy‐1H‐indol‐3ylmethylene)‐N‐pentyl‐carbazimidamide), an aminoguanidine indole derivative of serotonin, is a selective partial agonist highly selective for 5‐HT4 receptor with an affinity constant in the nanomolar range. Tegaserod, by acting as an agonist at neuronal 5-HT4 receptors, triggers the release of further neurotransmitters such as calcitonin gene-related peptide from sensory neurons. The activation of 5-HT4 receptors in the gastrointestinal tract stimulates the peristaltic reflex and intestinal secretion, as well as inhibits visceral sensitivity. In vivo studies showed that tegaserod enhanced basal motor activity and normalized impaired motility throughout the gastrointestinal tract. Zelnorm® (tegaserod maleate) is indicated for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation. In addition Zelnorm® is indicated for the treatment of patients less than 65 years of age with chronic idiopathic constipation. — NCATS
Clinical trial activity
25 trials · 7 clinical orgs · 3 marketing orgs
Earliest trial started Jun 1, 2003 (NCT00171418)
Timeline
2000s
- Jul 24, 2002
Novartis — Earliest FDA Approval
- Jul 24, 2002
Novartis — NDA Organization
- Jul 24, 2002
US WorldMeds — NDA Secondary Org
- Jul 24, 2002
Alfasigma S.p.A. — Marketing Organization
- Jul 24, 2002
Alfasigma S.p.A. — NDA Secondary Org
- Jan 1, 2003
- Jan 1, 2004
Indications
Mechanism of action
- Serotonin 4 (5-HT4) receptorPARTIAL AGONIST
HTR4 partial agonist
Approval history
- approvedPriority reviewJul 24, 2002
Chemistry & pharmacology
SMILES
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12- Mol. weight
- 301.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL76370 ↗
- WikipediaTegaserod ↗
- NCATSE5XNT3RF5A ↗
- ChEMBLCHEMBL1516474 ↗
Also known as
- 1-(((5-methoxyindol-3-yl)methylene)amino)-3-pentylguanidine
- 1-(((5-methoxyindol-3-yl)methylene)amino)-3-pentylguanidine
- 5-methoxyindol-3-carboxaldehyde amino(pentylamino)methylenehydrazone hydrogen maleate
- htf 919
- htf 919
- htf-919
- htf-919
- sdz htf 919
- sdz htf-919
- sdz-htf-919
- sdz-htf-919
- tegaserod
- tegaserod
- tegaserod
- tegaserod
- tegaserod
- tegaserod
- tegaserod
- tegaserod
- tegaserod
- tegaserod
- tégasérod
- tégasérod
- tegaserod maleate
- tegaserod maleate
- tegaserod maleate
- tegaserod maleate
- tegaserod maleate
- tegaserod maleate
- tegaserod maleate
- tegaserodum
- tegaserodum
- zelmac
- zelmac
- zelmac
- zelnorm
- zelnorm
- zelnorm
- zelnorm
- zelnorm
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00511771 | N/A | Aug 3, 2007 | Novartis |
| NCT00414024 | Phase 3 | Feb 1, 2007 | Novartis |
| NCT00390975 | Phase 4 | Jan 1, 2007 | Novartis |
| NCT00399659 | Phase 3 | Nov 1, 2006 | Novartis |
| NCT00365820 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2006 | Novartis |
| NCT00348634 | Phase 4 | Jul 1, 2006 | Novartis, Temple University, University of Michigan |
| NCT00277550 | Phase 4 | Jan 13, 2006 | Mayo Clinic, Novartis |
| NCT00171522 | Phase 4 | May 1, 2005 | Novartis |
| NCT00171457 | Phase 3 | Apr 1, 2005 | Novartis |
| NCT00171470 | Phase 3 | Apr 1, 2005 | Novartis |
| NCT00139568 | Phase 3 | Feb 1, 2005 | Novartis |
| NCT00563758 | N/A | Dec 1, 2004 | Government of Hong Kong, Novartis, The University of Hong Kong |
| NCT00171431 | Phase 3 | Nov 1, 2004 | Novartis |
| NCT00563615 | N/A | Nov 1, 2004 | Government of Hong Kong, Novartis, University of Toronto |
| NCT00232037 | Phase 3 | Sep 1, 2004 | Novartis |
| NCT00232102 | Phase 3 | Sep 1, 2004 | Novartis |
| NCT00232089 | Phase 3 | May 1, 2004 | Novartis |
| NCT00142974 | Phase 2 | May 1, 2004 | Novartis |
| NCT00149877 | Phase 4 | Apr 1, 2004 | Novartis |
| NCT00142987 | Phase 4 | Apr 1, 2004 | Novartis |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 25 | 23 | 4 | 2003 |
| Government of Hong Kong | Government | 2 | 2 | 1 | 2004 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| The University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2004 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alfasigma S.p.A. | For profit | MKTG | Jul 24, 2002 |
| Alfasigma S.p.A. | For profit | NDA2 | Jul 24, 2002 |
| Novartis | For profit | NDA | Jul 24, 2002 |
| US WorldMeds | For profit | NDA2 | Jul 24, 2002 |